dexamethasone zentiva 4 mg tablett
zentiva k.s. - dexametason - tablett - 4 mg - laktosmonohydrat hjälpämne; dexametason 4 mg aktiv substans
zeqmelit 6 mg munsönderfallande film
acucort ab - dexametason - munsönderfallande film - 6 mg - glycerol hjälpämne; dexametason 6 mg aktiv substans
zeqmelit 4 mg munsönderfallande film
acucort ab - dexametason - munsönderfallande film - 4 mg - dexametason 4 mg aktiv substans; glycerol hjälpämne
zeqmelit 8 mg munsönderfallande film
acucort ab - dexametason - munsönderfallande film - 8 mg - dexametason 8 mg aktiv substans; glycerol hjälpämne
dexametason 2care4 4 mg tablett
2care4 aps - dexametason - tablett - 4 mg - dexametason 4 mg aktiv substans; laktosmonohydrat hjälpämne
dexametason rosemont 2 mg/ml oral lösning
rosemont pharmaceuticals ltd - dexametasonnatriumfosfat - oral lösning - 2 mg/ml - sorbitol hjälpämne; maltitol, flytande hjälpämne; bensoesyra hjälpämne; propylenglykol hjälpämne; dexametasonnatriumfosfat aktiv substans - dexametason
dexalcex 4 mg/ml injektions-/infusionsvätska, lösning
as kalceks - dexametasonnatriumfosfat - injektions-/infusionsvätska, lösning - 4 mg/ml - dexametasonnatriumfosfat 4,37 mg aktiv substans
dexametason 2care4 4 mg tablett
2care4 aps - dexametason - tablett - 4 mg - dexametason 4 mg aktiv substans; laktosmonohydrat hjälpämne
dexametason ebb 4 mg tablett
ebb medical ab - dexametason - tablett - 4 mg - dexametason 4 mg aktiv substans; laktosmonohydrat hjälpämne
lenalidomide krka d.d. novo mesto (previously lenalidomide krka)
krka, d.d., novo mesto - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - immunsuppressiva - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) är indicerat för behandling av vuxna patienter med tidigare obehandlat multipelt myelom som inte är berättigade till transplantation. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) är indicerat för behandling av vuxna patienter med tidigare obehandlat multipelt myelom som inte är berättigade till transplantation. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).